[1]
S. Mangilipally, “Regulatory Pathways for Generic Antiviral Drugs: ANDA Requirements in the USA Compared With BRICS”, Int J Life Sci Pharm Res, vol. 16, no. 3, pp. 64–75, Nov. 2026.